对透明细胞肾细胞癌中PD-1/PD-L1阻断疗法临床转化的批判性洞察
A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.
作者信息
Nunes-Xavier Caroline E, Angulo Javier C, Pulido Rafael, López José I
机构信息
Biomarkers in Cancer Unit, Biocruces-Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain.
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
出版信息
Curr Urol Rep. 2019 Jan 15;20(1):1. doi: 10.1007/s11934-019-0866-8.
PURPOSE OF REVIEW
Targeting PD-1/PD-L1 immune checkpoints is a new therapeutic tool in patients with locally advanced and metastatic clear cell renal cell carcinoma (CCRCC). The purpose of this review is to offer clinicians an updated translational insight into the current status of a therapeutic alternative that may impact significantly patient's life.
RECENT FINDINGS
Immune checkpoint inhibition has recently demonstrated promising results in selected CCRCC patients with respect to tumor progression and survival. The decision to treat these patients with immune checkpoint inhibitors (ICI) relies on the immunohistochemical detection of PD-1/PD-L1 positivity in inflammatory cells in the tumor, which makes the role of the pathologist crucial, but clinical concern upon the reliability to use immunohistochemistry (IHC) to predict therapeutic response is increasing. We review the state of the art of the immune checkpoint inhibition in CCRCC, from the basic science and its fundamentals to the daily application in clinical routine.
综述目的
针对程序性死亡蛋白1（PD-1）/程序性死亡配体1（PD-L1）免疫检查点是局部晚期和转移性透明细胞肾细胞癌（CCRCC）患者的一种新型治疗手段。本综述旨在为临床医生提供关于一种可能显著影响患者生活的治疗选择的最新转化见解。
最新发现
免疫检查点抑制最近在部分CCRCC患者的肿瘤进展和生存方面显示出了有前景的结果。使用免疫检查点抑制剂（ICI）治疗这些患者的决策依赖于肿瘤中炎性细胞中PD-1/PD-L1阳性的免疫组化检测，这使得病理学家的作用至关重要，但对于使用免疫组化（IHC）预测治疗反应的可靠性的临床担忧日益增加。我们回顾了CCRCC中免疫检查点抑制的最新进展，从基础科学及其原理到临床常规中的日常应用。
Zotero 插件